Q3136976 (Q3136976): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): The development of new biomarkers is one of the axes of personalised medicine research that, especially in Oncology, allows a large number of patients, also in our country, to have more effective and safe therapies adapted to molecular findings in tissue samples obtained for diagnostic or therapeutic purposes. Other medical specialties are incorporating molecular imaging-based diagnosis, treatments based on targeted therapies, and new generation...) |
||||||||||||||
| Property / summary | |||||||||||||||
The development of new biomarkers is one of the axes of personalised medicine research that, especially in Oncology, allows a large number of patients, also in our country, to have more effective and safe therapies adapted to molecular findings in tissue samples obtained for diagnostic or therapeutic purposes. Other medical specialties are incorporating molecular imaging-based diagnosis, treatments based on targeted therapies, and new generations of agents are expected to combine diagnostic and therapeutic function (therapeutic). Biobanks that store clinical biological samples have the responsibility to provide researchers with samples of known quality and estimated potential for use in DNA, RNA, protein and antigenicity analysis. A key element for this purpose is the knowledge, control and recording of the pre-analytical factors that affect the subsequent analytical performance of the samples, taking into account the great diversity of tissues from which they come, the different forms with which they are obtained (biopsy, resection or post-mortem) and the wide range of analytical determinations in which they will be used. The OPTIMARK project aims, retrospectively, to analyse the current potential of samples stored in biobanks of the National Biobank Network Platform and its correlation with international consensus coding systems that include pre-analytical variables; and prospectively, to develop optimised protocols for sampling of different origins, control of key pre-analytical factors, and evaluation (algorithms of evaluation) of biomarker-related analytes. (English) | |||||||||||||||
| Property / summary: The development of new biomarkers is one of the axes of personalised medicine research that, especially in Oncology, allows a large number of patients, also in our country, to have more effective and safe therapies adapted to molecular findings in tissue samples obtained for diagnostic or therapeutic purposes. Other medical specialties are incorporating molecular imaging-based diagnosis, treatments based on targeted therapies, and new generations of agents are expected to combine diagnostic and therapeutic function (therapeutic). Biobanks that store clinical biological samples have the responsibility to provide researchers with samples of known quality and estimated potential for use in DNA, RNA, protein and antigenicity analysis. A key element for this purpose is the knowledge, control and recording of the pre-analytical factors that affect the subsequent analytical performance of the samples, taking into account the great diversity of tissues from which they come, the different forms with which they are obtained (biopsy, resection or post-mortem) and the wide range of analytical determinations in which they will be used. The OPTIMARK project aims, retrospectively, to analyse the current potential of samples stored in biobanks of the National Biobank Network Platform and its correlation with international consensus coding systems that include pre-analytical variables; and prospectively, to develop optimised protocols for sampling of different origins, control of key pre-analytical factors, and evaluation (algorithms of evaluation) of biomarker-related analytes. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The development of new biomarkers is one of the axes of personalised medicine research that, especially in Oncology, allows a large number of patients, also in our country, to have more effective and safe therapies adapted to molecular findings in tissue samples obtained for diagnostic or therapeutic purposes. Other medical specialties are incorporating molecular imaging-based diagnosis, treatments based on targeted therapies, and new generations of agents are expected to combine diagnostic and therapeutic function (therapeutic). Biobanks that store clinical biological samples have the responsibility to provide researchers with samples of known quality and estimated potential for use in DNA, RNA, protein and antigenicity analysis. A key element for this purpose is the knowledge, control and recording of the pre-analytical factors that affect the subsequent analytical performance of the samples, taking into account the great diversity of tissues from which they come, the different forms with which they are obtained (biopsy, resection or post-mortem) and the wide range of analytical determinations in which they will be used. The OPTIMARK project aims, retrospectively, to analyse the current potential of samples stored in biobanks of the National Biobank Network Platform and its correlation with international consensus coding systems that include pre-analytical variables; and prospectively, to develop optimised protocols for sampling of different origins, control of key pre-analytical factors, and evaluation (algorithms of evaluation) of biomarker-related analytes. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 13:59, 12 October 2021
Project Q3136976 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3136976 in Spain |
Statements
16,400.0 Euro
0 references
20,500.0 Euro
0 references
80.0 percent
0 references
1 January 2017
0 references
31 March 2020
0 references
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
0 references
37°8'35.23"N, 3°37'39.83"W
0 references
18021
0 references
El desarrollo de nuevos biomarcadores es uno de los ejes de la investigación en medicina personalizada que, especialmente en Oncología, permite que un gran número de pacientes, también en nuestro país, dispongan de terapias más eficaces y seguras, adaptadas a los hallazgos moleculares en muestras de tejido obtenidas con fines diagnósticos o terapéuticos. Otras especialidades médicas van incorporando diagnóstico basado en imagen molecular, tratamientos basados en terapias dirigidas, y es previsible que nuevas generaciones de agentes combinen la función diagnóstica con la terapéutica (teranósticos). Los biobancos que almacenan muestras biológicas clínicas tienen la responsabilidad de ofrecer a los investigadores muestras de calidad conocida y con un potencial estimado para su uso en análisis de ADN, ARN, proteínas y antigenicidad. Un elemento clave para este fin es el conocimiento, control y registro de los factores pre-analíticos que afectan al posterior rendimiento analítico de las muestras, teniendo en cuenta la gran diversidad de tejidos de los que proceden, las diferentes formas con que son obtenidas (biopsia, resección o post mortem) y el amplio rango de determinaciones analíticas en las que serán utilizadas. El proyecto OPTIMARK está dirigido, retrospectivamente, a analizar el potencial actual de muestras almacenadas en biobancos de la Plataforma Red Nacional de Biobancos y su correlación con sistemas de codificación de consenso internacional que incluyen variables pre-analíticas; y prospectivamente, a desarrollar protocolos optimizados para la toma de muestras de diferentes orígenes, el control de factores pre-analíticos claves, y la evaluación (algoritmos de evaluación) de analitos relacionados con biomarcadores. (Spanish)
0 references
The development of new biomarkers is one of the axes of personalised medicine research that, especially in Oncology, allows a large number of patients, also in our country, to have more effective and safe therapies adapted to molecular findings in tissue samples obtained for diagnostic or therapeutic purposes. Other medical specialties are incorporating molecular imaging-based diagnosis, treatments based on targeted therapies, and new generations of agents are expected to combine diagnostic and therapeutic function (therapeutic). Biobanks that store clinical biological samples have the responsibility to provide researchers with samples of known quality and estimated potential for use in DNA, RNA, protein and antigenicity analysis. A key element for this purpose is the knowledge, control and recording of the pre-analytical factors that affect the subsequent analytical performance of the samples, taking into account the great diversity of tissues from which they come, the different forms with which they are obtained (biopsy, resection or post-mortem) and the wide range of analytical determinations in which they will be used. The OPTIMARK project aims, retrospectively, to analyse the current potential of samples stored in biobanks of the National Biobank Network Platform and its correlation with international consensus coding systems that include pre-analytical variables; and prospectively, to develop optimised protocols for sampling of different origins, control of key pre-analytical factors, and evaluation (algorithms of evaluation) of biomarker-related analytes. (English)
12 October 2021
0 references
Armilla
0 references
Identifiers
PI16_01207
0 references